---
title: "Genetic Technologies to Wind Down U.S. ADR Program Amid ASX Trading Suspension"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290366073.md"
description: "Genetic Technologies announced that its depositary, Bank of New York Mellon, will terminate the company's Level 1 ADR facility on September 9, 2026. Holders can surrender ADRs for underlying ASX shares until at least September 13, 2027. However, since ASX trading is suspended, the depositary likely cannot realize value from remaining shares. This winds down the U.S. program, further limiting liquidity for investors."
datetime: "2026-06-22T00:42:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290366073.md)
  - [en](https://longbridge.com/en/news/290366073.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290366073.md)
generator: "portal-rs"
---

# Genetic Technologies to Wind Down U.S. ADR Program Amid ASX Trading Suspension

Genetic Technologies ( (AU:GTG) ) has shared an announcement.

Genetic Technologies Limited has announced that its depositary, Bank of New York Mellon, will terminate the company’s Level 1 American Depositary Receipt facility, which currently covers about 4.2 million ADRs, at 5:00 p.m. Eastern Time on 9 September 2026. Each ADR represents thirty ordinary shares, and holders will retain the right to surrender their ADRs for the underlying Australian-listed shares until at least 13 September 2027, subject to specified fees and applicable taxes.

After that date, the depositary may attempt to sell any remaining underlying ordinary shares and distribute net proceeds to holders who surrender their ADRs, though the company notes that its ordinary shares are currently suspended from trading on the ASX and there is no expectation that the depositary will be able to realise value from such sales. The move effectively winds down Genetic Technologies’ U.S. depositary program and further limits liquidity options for ADR investors, while the status of the company’s issued ordinary shares remains formally unchanged but constrained by the ongoing trading suspension.

**More about Genetic Technologies**

Genetic Technologies Limited is an Australia-based biotechnology company listed on the ASX, focused on genetic testing and related technologies. The company’s ordinary shares trade on the Australian market, while it has also maintained a Level 1 American Depositary Receipt program in the U.S. to provide access for international investors.

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$5.67M

### Related Stocks

- [GENE.US](https://longbridge.com/en/quote/GENE.US.md)
- [GTG.AU](https://longbridge.com/en/quote/GTG.AU.md)

## Related News & Research

- [Cobre Limited Seeks ASX Quotation for 13 Million New Shares](https://longbridge.com/en/news/296568613.md)
- [Lowell Resources Fund Lodges 2026 Corporate Governance Statement with ASX](https://longbridge.com/en/news/296569910.md)
- [Optomed Oyj (HEL:OPTOMED) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year](https://longbridge.com/en/news/296297835.md)
- [Himalaya Shipping shares trade ex-cash distribution of US$ 0.22 on Euronext Oslo Bors](https://longbridge.com/en/news/296444857.md)
- [MTN Rwanda releases H1 2026 results on Rwanda Stock Exchange](https://longbridge.com/en/news/296245062.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**